Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Fautrel

Showing results (131-140 of 370) with videos related to

Pageof 37
Sort By:
Joint Bone Spine|August 7, 2020
Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIRJoanna Kedra, Benjamin Granger, Stéphanie Emilie, et al.
Joint Bone Spine|July 6, 2005
Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in FranceBruno Fautrel, Marie-Christine Woronoff-Lemsi, Morgane Ethgen, et al.
Annals of the Rheumatic Diseases|June 16, 2019
Alcohol is not the missing link between <i>Porphyromonas gingivalis</i>-related periodontitis and radiological progression in early rheumatoid arthritisJulien Hillion, Alexandre Bellier, Xavier Romand, et al.
Joint Bone Spine|February 16, 2023
Variability of factors associated with grip strength in hand osteoarthritis according to sex: Results from the DIGICOD cohortElina Tan, Sophie Tuffet, Alexandra Rousseau, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohortCécile Escalas, Marie Dalichampt, Bernard Combe, et al.
Rheumatology Advances in Practice|May 1, 2023
Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE studyBruno Fautrel, Yoram Bouhnik, Philippe Dieude, et al.
Pharmacoeconomics|July 27, 2018
Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee OsteoarthritisJean-Hugues Salmon, Anne-Christine Rat, Isabelle Charlot-Lambrecht, et al.
Annals of the Rheumatic Diseases|March 16, 2012
Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohortCécile Gaujoux-Viala, Anne-Christine Rat, Francis Guillemin, et al.
Rheumatology (Oxford, England)|December 16, 2017
Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countriesErnest Choy, Roberto Caporali, Ricardo Xavier, et al.
RMD Open|June 23, 2022
Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare databaseRaphaele Seror, Alexandre Lafourcade, Yann De Rycke, et al.
Pageof 37

Showing results (131-140 of 370) with videos related to

Sort By:
Pageof 37
Joint Bone Spine|August 7, 2020
Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIRJoanna Kedra, Benjamin Granger, Stéphanie Emilie, et al.
Joint Bone Spine|July 6, 2005
Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in FranceBruno Fautrel, Marie-Christine Woronoff-Lemsi, Morgane Ethgen, et al.
Annals of the Rheumatic Diseases|June 16, 2019
Alcohol is not the missing link between <i>Porphyromonas gingivalis</i>-related periodontitis and radiological progression in early rheumatoid arthritisJulien Hillion, Alexandre Bellier, Xavier Romand, et al.
Joint Bone Spine|February 16, 2023
Variability of factors associated with grip strength in hand osteoarthritis according to sex: Results from the DIGICOD cohortElina Tan, Sophie Tuffet, Alexandra Rousseau, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohortCécile Escalas, Marie Dalichampt, Bernard Combe, et al.
Rheumatology Advances in Practice|May 1, 2023
Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE studyBruno Fautrel, Yoram Bouhnik, Philippe Dieude, et al.
Pharmacoeconomics|July 27, 2018
Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee OsteoarthritisJean-Hugues Salmon, Anne-Christine Rat, Isabelle Charlot-Lambrecht, et al.
Annals of the Rheumatic Diseases|March 16, 2012
Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohortCécile Gaujoux-Viala, Anne-Christine Rat, Francis Guillemin, et al.
Rheumatology (Oxford, England)|December 16, 2017
Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countriesErnest Choy, Roberto Caporali, Ricardo Xavier, et al.
RMD Open|June 23, 2022
Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare databaseRaphaele Seror, Alexandre Lafourcade, Yann De Rycke, et al.
Pageof 37